Jay Bradner
MD
President
👥Biography 个人简介
Jay Bradner at Novartis developed JQ1 — the first potent BET bromodomain inhibitor — and demonstrated that BET inhibition suppresses MYC transcription in cancer cells, providing an indirect strategy to target the 'undruggable' MYC oncogene. His chemical biology approach to cancer epigenetic drug discovery, and his decision to publish JQ1 as an open tool (rather than patent it for personal gain), catalyzed a major BET inhibitor research field and influenced scientific data sharing norms.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Jay Bradner 的研究动态
Follow Jay Bradner's research updates
留下邮箱，当我们发布与 Jay Bradner（Novartis Institutes for BioMedical Research）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment